Unique ID issued by UMIN | UMIN000023499 |
---|---|
Receipt number | R000026735 |
Scientific Title | Effect of a grain-derived processed product on visceral fat area |
Date of disclosure of the study information | 2016/08/28 |
Last modified on | 2019/07/30 13:15:05 |
Effect of a grain-derived processed product on visceral fat area
Effect of a grain-derived processed product on visceral fat area
Effect of a grain-derived processed product on visceral fat area
Effect of a grain-derived processed product on visceral fat area
Japan |
healthy humans
Adult |
Others
NO
To investigate the effect of grain-derived processed product on visceral fat area
Efficacy
visceral fat area
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
control: product code;P-001
12-wk repeated consumption and 4-wk post treatment observation.
Dose of 1 serving per day.
Visceral fat area measurement every 4-wk.
Active: product code;S-001
12-wk repeated consumption and 4-wk post treatment observation.
Dose of 1 serving per day.
Visceral fat area measurement every 4-wk.
30 | years-old | <= |
65 | years-old | > |
Male and Female
1,25<=BMI<30
2,visceral fat area=>100cm2
3,30<=Age<65 of healthy men and women
4,provided written informed consent from subjects
1,liver, kidney and heart disease, or disorder of respiration, endocrine, metabolism, nervous system, consciousness, or diabetes, or other diseases
2,surgery or therapy within 2 months before the trial
3,medicine user for hyperglycaemia, lipidemia, or hypertension
4,user of supplements or foods with health claim,
5,unpleasant feeling during blood drawing
6,donated 200 mL or more blood within 1 month before the trial
7,skin disease, metal allergy and implanted pacemaker
8,remain constipated 5 days and more
9,changes in weight of 2kg or more within 3 month before the study
10,shift worker
11,business trip and travel planned for 10 consecutive days or more
12,allergies against any constituents in the test diet
13,other clinical study or who intended to participate in one during the study period
14,disagree with explanation for study
15,judged to be inappropriate as subject by physician in charge
120
1st name | Hirona |
Middle name | |
Last name | Miura |
Higashi shinjyuku Clinic
Director
169-0072
1-11-3 Okubo Shinjuku-ku Tokyo
03-6233-8581
koike@meiseikai-cl.com
1st name | Shimpei |
Middle name | |
Last name | Tomita |
New Drug Research Center, Inc.
Research Division
061-1405
452-1, Toiso, Eniwa-shi, Hokkaido
0123-34-0412
s-tomita@ndrcenter.co.jp
Higashi shinjyuku Clinic
Kao Corporation
Profit organization
Miyawaki orthopedics clinic IRB
3-1-6 Ariakecho, Eniwa-city, Hokkaido
0123-35-3011
d-kameda@mediffom.co.jp
NO
2016 | Year | 08 | Month | 28 | Day |
Unpublished due to the protocol including the intellectual property rights
Unpublished
works in progress
120
There was a significant difference in primary outcome
2019 | Year | 07 | Month | 30 | Day |
overweight
114 participants completed and 111 subjects were incorporated into the analyses
No adverse effect related to the test diets reported
visceral fat area
Completed
2016 | Year | 07 | Month | 25 | Day |
2016 | Year | 07 | Month | 25 | Day |
2016 | Year | 08 | Month | 28 | Day |
2017 | Year | 01 | Month | 09 | Day |
2016 | Year | 08 | Month | 05 | Day |
2019 | Year | 07 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026735